



DRAXIMAGE Inc.,
16751 TransCanada Highway
Kirkland,
Quebec H9H 4J4
Tel.: (514) 630-7043

FACSIMILE TRANSMISSION

Addressee: Mr Seung J. Lee,
Materials Safety and Inspection Branch,
Division of Industrial and Medical Nuclear Safety,
Office of Nuclear Material Safety and Safeguards,
United States Nuclear Regulatory Commission,
Washington,
DC 20555-0001

Fax No: (301) 415-5369

Date: August 24, 2000

Sender: Dr Richard J. Flanagan
Fax No: 514-630-7039
Phone No: 514-694-9295
e-mail: rflanagan@draximage.com

This Transmission Contains 3 Page(s)

Message: Dear Mr. Leung,

Please find attached as promised, the 510(K) approval from the FDA, which we received yesterday.

Sincerely,

A handwritten signature in black ink, appearing to read "Richard J. Flanagan".

Richard J. Flanagan Ph.D.
Exec. Vice President.

Confidentiality: This message is intended for the use of the individual or entity to which it is addressed and may contain certain information which is privileged. Confidentiality and privilege are not lost by this facsimile having been sent to the wrong person. If you are not the intended recipient or the person to deliver it to the intended recipient, please notify 514-630-7186 and return this facsimile to us by mail. Any distribution, reproduction or other use of this facsimile by an unintended recipient is prohibited.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

AUG 22 2000

Richard J. Flanagan, Ph.D.
Executive Vice President
DraxImage Inc.
16751 Autoroute TransCanada Highway
Kirkland, Quebec
Canada H9H 4J4

Re: K000475
BrachySeed™ (I-25 Brachytherapy Source)
Dated: June 12, 2000
Received: June 15, 2000
Regulatory class: II
21 CFR 892.5730/Procode: 90 KXX

Dear Dr. Flanagan:

We have reviewed your Section 510(k) notification of Intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for *in vitro* diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4539. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "<http://www.fda.gov/cdrh/dsm/dsmmain.html>".

Sincerely yours,

Daniel G. Schultz, M.D.
Captain, USPHS
Director, Division of Reproductive,
Abdominal, and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure(s)

DRAXIMAGE	February 14, 2000	Page 9-1
510(k) Premarket Notification to FDA for BrachySeed™		

SECTION 9 - STATEMENT OF INDICATIONS FOR USE

Page 1 of 1Applicant: DRAXIMAGE INC.510(k) Number (if known): K000475Device Name: BrachySeed™

Indications for Use:


Draft: BrachySeeds with air kerma strengths up to 1.25U (approx. 1mCi apparent activity) are indicated for permanent interstitial implantation in the treatment of selected localized tumors such as tumors of the head, neck, lung, pancreas, breast, uterus, and prostate. They can be used either as primary treatment or for residual disease after excision of the primary tumor or for recurring tumors. They may also be used at completion of external beam radiation.

BrachySeeds with strengths greater than 1.25U (approx. 1mCi) are indicated for temporary implantation or surface application to treat localized tumors.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Per 21 CFR 801.109)



 (Division Sign-Off)

Division of Reproductive, Abdominal, ENT,
and Radiological Devices

510(k) Number K000475

Prescription Use
 (Per 21 CFR 801.1091)

OR

Over-The-Counter Use